Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  OTC Bulletin Board  >  La Jolla Pharmaceutical Company    LJPCD

No quotes available
-- USD   0.00%
07/22 LA JOLLA PHARMA : Therapeutics strategies and Product Pipeline Revie..
06/06 LA JOLLA PHARMA : to Provide Corporate Overview at the Jefferies 201..
05/26 LA JOLLA PHARMA : Insiders are Gradually Buying u
SummaryQuotesNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

LA JOLLA PHARMACEUTICAL : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/15/2015 | 10:04pm CEST

ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.

On September 9, 2015, La Jolla Pharmaceutical Company ("We," "La Jolla" or the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Jefferies LLC and Cowen and Company, LLC, as representatives of the several underwriters (the "Underwriters"), pursuant to which we agreed to issue and sell an aggregate of 2,932,500 shares, including 382,500 shares to be sold pursuant to the exercise by the Underwriters of the option we granted the Underwriters to purchase such shares, of our common stock (the "Shares") to the Underwriters (the "Offering"). The Shares were sold at a public offering price of $38.00 per Share, and were purchased by the Underwriters from us at a price of $35.72 per Share. On September 11, 2015, the underwriters exercised their option to purchase an additional 382,500 shares of our common stock.

We estimate that net proceeds we will receive from the Offering, including the proceeds from the additional 382,500 shares that will be purchased by the underwriters following the exercise of their option, will be approximately $104.7 million, after deducting the Underwriters' discounts and commissions and estimated offering expenses payable by us.

The Offering was made pursuant to La Jolla's effective registration statement on Form S-3 (Registration No. 333-197092), which was previously filed with the Securities and Exchange Commission ("SEC") under the Securities Act of 1933, as amended (the "Securities Act"), and was declared effective, a related automatically effective registration statement filed with the SEC pursuant to Rule 462(b) of the Securities Act (File No. 333-206855), and a prospectus supplement filed with the SEC.

The Offering closed on September 15, 2015. In the Underwriting Agreement, the Company agreed to indemnify the Underwriters against certain liabilities, including liabilities under the Securities Act or to contribute to payments that the Underwriters may be required to make because of such liabilities.

A copy of the Underwriting Agreement is attached as Exhibit 1.1 hereto and is incorporated herein by reference. The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit.

A copy of the opinion of Gibson, Dunn & Crutcher LLP relating to the validity of the securities issued in the Offering is filed herewith as Exhibit 5.1.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.



(d) Exhibits.



Exhibit
  No.        Description

 1.1         Underwriting Agreement, dated September 9, 2015, among La Jolla
             Pharmaceutical Company and Jefferies LLC and Cowen and Company, LLC,
             as representatives of the several underwriters named therein

 5.1         Opinion of Gibson, Dunn & Crutcher LLP

23.1         Consent of Gibson, Dunn & Crutcher (contained in Exhibit 5.1)




                                   *   *   *

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LA JOLLA PHARMACEUTICAL CO
07/22 LA JOLLA PHARMACEUTICAL COMPANY : Therapeutics strategies and Product Pipeline R..
06/06 LA JOLLA PHARMACEUTICAL COMPANY : to Provide Corporate Overview at the Jefferies..
05/26 LA JOLLA PHARMACEUTICAL : Insiders are Gradually Buying u
05/07 LA JOLLA PHARMACEUTICAL COMPANY : Basic Consolidated EPS At $-2.6779
05/06 LA JOLLA PHARMACEUTICAL : posts 1Q loss
05/06 LA JOLLA PHARMACEUTICAL COMPANY : Announces First Quarter 2016 Financial Results..
03/03 LA JOLLA PHARMACEUTICAL : Announces Fourth Quarter and Full Year 2015 Financial ..
03/03 LA JOLLA PHARMACEUTICAL : to Provide Corporate Overview at the Cowen and Company..
02/26 LA JOLLA PHARMACEUTICAL : posts 4Q loss
02/25 LA JOLLA PHARMACEUTICAL : Announces Fourth Quarter and Full Year 2015 Financial ..
More news
Sector news : Bio Therapeutic Drugs
07/21DJAmgen and Allergan Study Finds Biosimilar Comparable to Herceptin
07/12DJAmgen Biosimilar Gets Thumbs-Up From FDA Panel
07/12DJJuno to Resume Clinical Trial of Anticancer Treatment
07/09DJCorrections & Amplifications -- WSJ
07/08DJAMGEN : Theranos Dealt Blow as Holmes Is Banned From -2-
More sector news : Bio Therapeutic Drugs
Advertisement
Financials ($)
Sales 2016 2,14 M
EBIT 2016 -71,4 M
Net income 2016 -71,3 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 137x
Capi. / Sales 2017 0
Capitalization 295 M
More Financials
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 40,0 $
Spread / Average Target 148%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
George Francis Tidmarsh President, CEO, Secretary & Director
Kevin C. Tang Chairman
Jennifer Carver Senior Vice President-Operations
Dennis M. Mulroy Chief Financial & Accounting Officer
James M. Rolke Vice President-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
LA JOLLA PHARMACEUTICA..0.00%295
AMGEN, INC.2.06%124 454
GILEAD SCIENCES, INC.-14.47%115 269
CELGENE CORPORATION-10.22%83 285
REGENERON PHARMACEUTIC..-27.91%41 121
VERTEX PHARMACEUTICALS..-25.38%23 224
More Results